MicroRNAs in peritoneal fibrosis: a systematic review.
MicroRNAs in peritoneal fibrosis: a systematic review.
复制标题
DOI：
--
复制
发表时间：
2018-12
影响因子：
1.4
通讯作者：
Katsunori Yanai;Hiroki Ishii;Akinori Aomatsu;K. Ishibashi;Yoshiyuki Morishita
中科院分区：
文献类型：
--
作者：
Katsunori Yanai;Hiroki Ishii;Akinori Aomatsu;K. Ishibashi;Yoshiyuki Morishita
腹膜纤维化是长期腹膜透析（PD）的重要并发症。腹膜纤维化导致腹膜衰竭的发展，导致PD退出。尚未建立针对腹膜纤维化的特异性生物标志物或疗法。microRNAs（miRNAs）是一类能够抑制靶信使RNA翻译的非编码小分子RNA。先前的研究表明，miRNAs在腹膜纤维化的发展中起关键作用，表明它们可能代表腹膜纤维化的潜在生物标志物和治疗选择。因此，这篇系统性综述的重点是miRNA在腹膜纤维化中的作用，关于它们作为生物标志物的潜力，以及miRNA调节作为一种治疗选择。
Peritoneal fibrosis is a crucial complication of long-term peritoneal dialysis (PD). Peritoneal fibrosis contributes to the development of peritoneal membrane failure, which leads to withdrawal from PD. No specific biomarkers or therapies have yet been established for peritoneal fibrosis. MicroRNAs (miRNAs) are small noncoding RNAs that can inhibit the translation of target messenger RNAs. Previous studies have shown that miRNAs play pivotal roles in the development of peritoneal fibrosis, indicating that they may represent potential biomarkers and therapeutic options for peritoneal fibrosis. Therefore, this systematic review focuses on miRNAs in peritoneal fibrosis, with regard to their potential as biomarkers, and miRNA modulation as a therapeutic option.